INCYTE Business Summary

Incyte Corp (INCY) is a global biopharmaceutical leader that generates revenue primarily through direct product sales (85.3%), third-party royalties (13.7%), and strategic R&D milestones. The company’s operations are bifurcated into two primary segments: Hematology/Oncology, anchored by the blockbuster JAK1/JAK2 inhibitor Jakafi (ruxolitinib), and Inflammation and Autoimmunity (IAI), driven by the rapid uptake of Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo. In 2025, Incyte surpassed $5.1 billion in total revenue, reflecting a 21% year-over-year increase as it aggressively diversifies its portfolio to mitigate the 2028 patent cliff of its core Jakafi franchise. The company competes directly with GSK (Ojjaara) in the myelofibrosis space, and with AbbVie (Rinvoq) and Eli Lilly (Olumiant) in the high-growth immunology and dermatology markets, positioning itself as a specialized mid-to-large cap innovator transitioning from a single-asset powerhouse to a multi-franchise commercial entity. Originally founded in 1991 and significantly reshaped in 2002 by veteran scientists from DuPont Merck, Incyte is currently led by President and CEO Bill Meury, a seasoned pharmaceutical executive who joined in 2025 following successful leadership roles at Anthos Therapeutics, Karuna Therapeutics, and Allergan. The executive team includes Dr. Pablo J. Cagnoni (President and Head of R&D), formerly CEO of Laronde and a veteran of Novartis Oncology, and Dr. Steven H. Stein, who serves as Executive VP and Chief Medical Officer. Strategic growth is further guided by Chief Strategy Officer Dave Gardner and General Counsel Richard Hoffman, both of whom joined in late 2025. The company maintains a high degree of institutional backing, notably from Baker Brothers Investments, whose managing partner Julian C. Baker serves as Chairman of the Board. Other prominent board members include former BioMarin CEO Jean-Jacques Bienaimé and former Novartis Oncology President Susanne Schaffert.